UNITED STATES

0001010412-11-000577.txt : 20111031 0001010412-11-000577.hdr.sgml : 20111031 20111031112043 ACCESSION NUMBER: 0001010412-11-000577 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110930 FILED AS OF DATE: 20111031 DATE AS OF CHANGE: 20111031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANCER CAPITAL CORP CENTRAL INDEX KEY: 0001130889 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 911803648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32363 FILM NUMBER: 111167057 BUSINESS ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 BUSINESS PHONE: 8013232395 MAIL ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 10-Q 1 ccap_11q3final.htm QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2011 UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 000-32363

CANCER CAPITAL CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

91-1803648

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip code)

(801) 323-2395

(Registrant’s telephone number, including area code)

The registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]

Non-accelerated filer [ ]

Accelerated filer [ ]

Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [X] No [ ]

The number of shares outstanding of the registrant’s common stock as of October 27, 2011 was 6,150,000.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Balance Sheets

Condensed Statements of Operations

Condensed Statements of Cash Flows

Condensed Notes to the Financial Statements

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item 4. Controls and Procedures

PART II – OTHER INFORMATION

Item 5. Other Information

Item 6. Exhibits

Signatures

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The financial information set forth below with respect to our statements of operations for the three and nine month periods ended September 30, 2011 and 2010 is unaudited. This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data. The results of operations for the nine month period ended September 30, 2011, are not necessarily indicative of results to be expected for any subsequent period.

CANCER CAPITAL CORP.

(A Development Stage Company)

Financial Statements

September 30, 2011

Cancer Capital Corp.

(A Development Stage Company)

Balance Sheets

(Unaudited)


		September 30, 2011		December 31, 2010
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	897	$	2,007
Total current assets		897		2,007
Total assets	$	897	$	2,007

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable - related party	$	9,750	$	9,750
Accounts payable		43,425		38,600
Total current liabilities		53,175		48,350
Total liabilities		53,175		48,350

STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding		6,150		6,150
Additional paid-in capital		47,050		47,050
Deficit accumulated during the development stage		(105,478)		(99,543)
Total stockholders' deficit		(52,278)		(46,343)
Total liabilities and stockholders' deficit	$	897	$	2,007

The accompany notes are an integral part of these financial statements

Cancer Capital Corp.

(Development Stage Company)

Statements of Operations

(Unaudited)



		For the three months ended September 30, 2011		For the three months ended September 30, 2010		For the nine months ended September 30, 2011		For the nine months ended September 30, 2010		From Inception on April 11, 1997 to September 30, 2011

Revenues	$	0	$	0	$	0	$	0	$	0

Expenses
General and administrative		1,451		759		5,935		4,740		105,478
Total expenses		1,451		759		5,935		4,740		105,478

Net operating loss		(1,451)		(759)		(5,935)		(4,740)		(105,478)

Loss before taxes		(1,451)		(759)		(5,935)		(4,740)		(105,478)

Taxes		0		0		0		0		0

Net loss	$	(1,451)	$	(759)	$	(5,935)	$	(4,740)	$	(105,478)

Net loss per share	$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)

Weighted average shares outstanding		6,150,000		6,150,000		6,150,000		6,150,000

The accompany notes are an integral part of these financial statements

Cancer Capital Corp.

(A Development Stage Company)

Statements of Cash Flows

(Unaudited)



		For the nine months ended September 30, 2011		For the nine months ended September 30, 2010		From Inception on April 11, 1997 to September 30, 2011

Cash Flows from Operating Activities
Net Loss	$	(5,935)	$	(4,740)	$	(105,478)
Adjustment to reconcile net loss to cash provided (used) by operating activities:
Common stock issued for services		0		0		17,200
Changes in liabilities:
Increase in accounts payable and accrued expenses		4,825		7,900		53,175
Net cash provided (used) by operating activities		(1,110)		3,160		(35,103)

Cash Flows from Investing Activities
Net cash provided by investing activities		0		0		0

Cash Flows from Financing Activities
Proceeds from common stock issued for cash		0		0		36,000
Net cash provided by financing activities		0		0		36,000

Increase (Decrease) in cash		(1,110)		3,160		897

Cash and cash equivalents at beginning of period		2,007		1,230		0

Cash and cash equivalents at end of period	$	897	$	4,390	$	897

Supplemental Cash Flow Information:
Cash paid for interest	$	0	$	0	$	0
Cash paid for income taxes	$	0	$	0	$	0

Non-Cash Investing and Financing Activities
Common stock issued for services	$	0	$	0	$	17,200

Cancer Capital Corp.

(A Development Stage Company)

Notes to the Financial Statements

September 30, 2011

NOTE 1 -

BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2010 Annual Report on Form 10-K. Operating results for the nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for year ending December 31, 2011.

In this report references to “Cancer Capital,” “the Company,” “we,” “us,” and “our” refer to Cancer Capital Corp.

FORWARD LOOKING STATEMENTS

The Securities and Exchange Commission (“SEC”) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “intend,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Overview

We are a development stage company that has not recorded revenues for the past two fiscal years. At September 30, 2011 we had $897 in cash and total liabilities of $53,175. We are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

Management anticipates that the struggling global economy will restrict the number of business opportunities available to us and will restrict the cash available for such transactions. There can be no assurance in the current economy that we will be able to acquire an interest in an operating company.

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will

sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

Liquidity and Capital Resources

We have not recorded revenues from operations since our inception and we have not established an ongoing source of revenue sufficient to cover our operating costs. We intend to obtain capital from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Accounts payable have increased by $4,825 for the 2011 nine month period compared to December 31, 2010 primarily as a result of costs and services required to file our periodic reports. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and to acquire or enter into a merger with such company. The type of business opportunity which we acquire or merge with will affect our profitability for the long term.

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses or services.

Results of Operations

We had no revenues during the 2011 and 2010 three and nine month periods ended September 30. General and administrative expense increased from $759 for the 2010 third quarter to $1,451 for the 2011 third quarter primarily as a result of increased fees for preparation and filing of XBRL files with our prior periodic report. The increased periodic filing costs will likely continue in the short term. General and administrative expense increased from $4,740 for the 2010 nine month period to $5,935 for the 2011 nine month period. As a result, our net loss also increased for both the 2011 third quarter and 2011 nine month period.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness

of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were ineffective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

Changes to Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the third quarter of our 2011 fiscal year that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 5. OTHER INFORMATION

On September 13, 2011 we received notification from the Financial Industry Regulatory Authority (“FINRA”) that our common stock was cleared for listing on the OTC Bulletin Board under the symbol “CNCL.” Additional documentation and information must be provided to FINRA and the OTC Bulletin Board before we may start active trading and as of the date of this filing there has not been any trading activity in our common stock.

ITEM 6. EXHIBITS

Part I Exhibits


No.	Description
31.1	Principal Executive Officer Certification
31.2	Principal Financial Officer Certification
32.1	Section 1350 Certification

Part II Exhibits


No.	Description
3(i)	Articles of Incorporation (Incorporated by reference to exhibit 3.1 of Form 10-SB, File No. 000-32363, filed February 20, 2001)
3(ii)	Bylaws of Cancer Capital (Incorporated by reference to exhibit 3.2 of Form 10-SB, File No. 000-32363, filed February 20, 2001)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 31, 2011

CANCER CAPITAL CORP.

By: /s/John W. Peters______________________

John W. Peters

President and Director

Principal Financial Officer

EX-31 2 ex311.htm 302 CERTIFICATION OF CEO Exhibit 31

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2011

/s/John W. Peters____________________

John W. Peters

Principal Executive Officer

EX-31 3 ex312.htm 302 CERTIFICATION OF CFO Exhibit 31

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2011

/s/John W. Peters__________________

John W. Peters

Principal Financial Officer

EX-32 4 ex32.htm SECTION 1350 CERTIFICATION Exhibit 32

Exhibit 32.1

CANCER CAPITAL CORP.

CERTIFICATION OF PERIODIC REPORT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18 U.S.C. Section 1350

The undersigned executive officer of Cancer Capital Corp. certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

the quarterly report on Form 10-Q of Cancer Capital Corp. for the quarter ended September 30, 2011 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cancer Capital Corp.

Date: October 31, 2011

/s/John W. Peters__________________

John W. Peters

Principal Executive Officer

Principal Financial Officer

EX-101.INS 5 cncl-20110930.xml XBRL INSTANCE DOCUMENT 10-Q 2011-09-30 false CANCER CAPITAL CORP 0001130889 --12-31 6150000 Smaller Reporting Company Yes No No 2011 Q3

897

2007

897

2007

897

2007

9750

43425

38600

53175

48350

53175

48350

6150

47050

105478

99543

-52278

-46343

897

2007

1451

759

5935

4740

105478

1451

759

5935

4740

105478

-1451

-759

-5935

-4740

-105478

-1451

-759

-5935

-4740

-105478

-1451

-759

-5935

-4740

-105478

-0.00

6150000

0.001

20000000

6150000

17200

4825

7900

53175

-1110

3160

-35103

36000

-1110

3160

897

1230

4390

NOTE 1 -  BASIS OF FINANCIAL STATEMENT PRESENTATION                     The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations.  The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Companys audited financial statements and notes thereto included in its December 31, 2010 Annual Report on Form 10-K.  Operating results for the nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for year ending December 31, 2011.

0001130889 2011-07-01 2011-09-30 0001130889 2011-09-30 0001130889 2010-12-31 0001130889 2010-07-01 2010-09-30 0001130889 2011-01-01 2011-09-30 0001130889 2010-01-01 2010-09-30 0001130889 1997-04-11 2011-09-30 0001130889 2009-12-31 0001130889 1997-04-10 0001130889 2010-09-30 0001130889 2011-10-27 shares iso4217:USD iso4217:USD shares EX-101.LAB 6 cncl-20110930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Fiscal Period Focus General and administrative Common stock par value Net cash provided by financing activities Net cash provided by financing activities LIABILITIES AND STOCKHOLDERS' DEFICIT Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Organization, Consolidation and Presentation of Financial Statements Net cash provided by investing activities Net cash provided by investing activities STOCKHOLDERS' DEFICIT ASSETS Loss before taxes Net operating loss Net operating loss Total assets Total assets Statement [Table] Document Fiscal Year Focus Entity Well-known Seasoned Issuer Taxes Document Type Proceeds from common stock issued for cash Statement of Cash Flows Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding CURRENT LIABILITIES CURRENT ASSETS Cash Flows from Investing Activities Common stock issued for services Document Period End Date Supplemental Cash Flow Information: Total current liabilities Total current liabilities Total current assets Total current assets Common stock issued Statement of Financial Position Cash paid for income taxes Cash Flows from Operating Activities Weighted average shares outstanding Net loss per share Accounts payable Net cash provided (used) by operating activities Net cash provided (used) by operating activities Expenses Accounts payable - related party Entity Current Reporting Status Entity Common Stock, Shares Outstanding Entity Registrant Name Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Increase in accounts payable and accrued expenses Net Loss Net loss Total stockholders' deficit Total stockholders' deficit Document and Entity Information Non-Cash Investing and Financing Activities Income Statement Deficit accumulated during the development stage Deficit accumulated during the development stage Additional paid-in capital Statement [Line Items] Entity Voluntary Filers Cash paid for interest Adjustment to reconcile net loss to cash provided (used) by operating activities: Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Entity Central Index Key Increase (Decrease) in cash Total expenses Total expenses Revenues Total liabilities Total liabilities Amendment Flag Cash Flows from Financing Activities Common stock authorized Entity Filer Category Current Fiscal Year End Date EX-101.CAL 7 cncl-20110930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 8 cncl-20110930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 124000 - Statement - Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 200000 - Disclosure - Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:definitionLink link:calculationLink 104000 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 152200 - Statement - Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink EX-101.PRE 9 cncl-20110930_pre.xml XBRL TAXONOMY PRESENTATION LINKBASE DOCUMENT EX-101.DEF 10 cncl-20110930_def.xml XBRL TAXONOMY DEFINITION LINKBASE DOCUMENT XML 11 R3.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (USD $)	Sep. 30, 2011	Dec. 31, 2010
CURRENT ASSETS
Cash and cash equivalents	$ 897	$ 2,007
Total current assets	897	2,007
Total assets	897	2,007
CURRENT LIABILITIES
Accounts payable - related party	9,750	9,750
Accounts payable	43,425	38,600
Total current liabilities	53,175	48,350
Total liabilities	53,175	48,350
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding	6,150	6,150
Additional paid-in capital	47,050	47,050
Deficit accumulated during the development stage	(105,478)	(99,543)
Total stockholders' deficit	(52,278)	(46,343)
Total liabilities and stockholders' deficit	$ 897	$ 2,007

XML 12 R4.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		176 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Revenues	$ 0	$ 0	$ 0	$ 0	$ 0
Expenses
General and administrative	1,451	759	5,935	4,740	105,478
Total expenses	1,451	759	5,935	4,740	105,478
Net operating loss	(1,451)	(759)	(5,935)	(4,740)	(105,478)
Loss before taxes	(1,451)	(759)	(5,935)	(4,740)	(105,478)
Taxes	0	0	0	0	0
Net loss	$ (1,451)	$ (759)	$ (5,935)	$ (4,740)	$ (105,478)
Net loss per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average shares outstanding	6,150,000	6,150,000	6,150,000	6,150,000

XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Sep. 30, 2011	Oct. 27, 2011
Document and Entity Information
Entity Registrant Name	CANCER CAPITAL CORP
Document Type	10-Q
Document Period End Date	Sep. 30, 2011
Amendment Flag	false
Entity Central Index Key	0001130889
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		6,150,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q3

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R6.htm IDEA: XBRL DOCUMENT

Organization, Consolidation and Presentation of Financial Statements

3 Months Ended

Sep. 30, 2011

Organization, Consolidation and Presentation of Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001010412-11-000577-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001010412-11-000577-xbrl.zip M4$L#!!0````(`)U:7S^B41&L^PL``&)2```1`!P`8VYC;"TR,#$Q,#DS,"YX M;6Q55`D``]J\KD[:O*Y.=7@+``$$)0X```0Y`0``W5QK;^,V%OT\"^Q_8+'` M9!>(;,F/.$XR4W@<9V!,ZJ1Q^IA/"T:B;;82I9*4$_?7[R7EAR0KEF7+<;`= M%+%$\IQS+R]?$L6K'U\\%TT)%]1GGTZLBGF""+-]A[+QIQ,J?./\O-DVK),? M/__S'U<_&`:ZY[X3VL1!3S/4N_[:>1`AE00)?R2?,2>GJ.-,,5,9NKX7A))P MU&?,GV()#.(4+NS**:0%,T['$XG^W?T/JIGFN5$S+:N"GI^?*\098ZYA*[;O M(<-0W"]/W$4@EHD+A]!/)Q,I@XMJ5=VN"&)7QOZT"@E5!6.8EE&W3N;91]1= M9N\.NKK.G61=2UG4H]*?L)BA0RIM(#^4!ACC(-EB1$63SKW M/"'#>Q`#C9K5VD02Y8AK)4*/22IG#V1,A>28R0'V,G5U.X-N[P%U._?]Q\XMZMX] MW$>P60`I]"Z0OI%9%KP)`6[5S?/S=APU57`)VPTY5X9086/W.\%\ M@T,-PZI!M$6PKQ5,"_8]SV=#Z=M_#B?0YXB[4*HX5YT6"AF-"**DDP1IWX+P MJ4&H.L2F'C@?;@UN3CZ?64TPT4P8MX$DI>>&NH1W0>?8YYGN&P(59$$/)/"Y M5"I5WXC9+$Z80$E;'#EF67XHL0Q%%M5W(A)69!9,H?_JNR&3F$<2,F$'?APU M52`%]QMQW6_,?V9#@H7/B-,7(@3K=+&8=)BC_O3^"ND4NU!$=&07PO MP^MDM/8T:3I6S]NMJVHABI)%F6N2H&O?2U-'""+%/%;W2/`/S.,JP MH"CL=IJ3J+;M0S,6]WB&GUSR0%SH?)Q[#!T%V;DRVJVF&6/=@J)<3>M^*%=1 M88R2'+];)P,RL!'L3,Y8\]/*DY,UR"BEY M@)A@X<;^^WNF\;'VO\`H#FP>!O@:%KCP[[^+)UR'8#`C!O-@#.V6V;!VMN$K M881C%P*@XWB4Z0K*KVVHTK15E#GII2K+BH]5LO[60G'AJ MMNO-MY>T,0`;K8;YYI(V1VQZ."XBJNL+J3JS>5KQWBH9OFFXW;ER`[0LJD(A M6!YI@2`KC;18&&VDO0N("BHV[C/;]\BM+XJ'CI&,G0S(O2BS(LA(A%"YC#F! M9"0CJ6SNC?%D)`.J9.[-866DXRJ/?77[AOM>%Y@H"R'[O)S/Q!0U-XW!/>@?A,3\D/Z?5M0K(F\=UN*-+EW;DO!)ERN-9`^'V.^P,QE M1#<]OY@SZ,/$/>'ZE?P7+!*=IG`6*5N%BUF)OR_) M!"^)/C.,WHH^+[[>3L?FN"NJXS>B]H\1IS.%(6U,!J'W1/C=:&VS1DI?UK:0 M[`!9;@K9B?%P6K.BZ7UJS0F]]RIZ8YR6*#KVINP>\SNN-N<01[\T6X3]%NTJ M^P&]:DV)QSZY5`>1EC$E*$U8Y.%.*"<^IW\39W.U9KNI9D;_90I*$Y0E)/,M M1EDR])ZIG7RQ%MFO8)?!OT6[VH9=W5+[6Z&YJ7P=YOR&N=KF*&Y\/B1\2FUH M@[SK8NJ5\]:D$..!M&X]Y3^^UIP'FJV:68Y>9G."U>O?Z&^?I;:_J$?MMLTA M?K;;N)$3$(WS6O(QR`[LAS9@8Y2TVJ;YS@W8'#JI;3HE6`#K#K5E\9[[4^H0 MY\OL%T&BA63NWG.S2#[A`JMQU`CJIRZR=+.ZJ$_#8ACGY`NAIY8K..4BHZEZ5$ M3=M6ZQMJVER)];/$C*^8KE>J_88R*/=F+3:#[A`J]VRQ;Z.R4&7OJ#3[XX+H M"XST)*"T<;H(Z6'4%ABKCRYV1^?,5?/V;PW?$Q9O1O_5Z\ZS/AN]31%Q#4]U`#$,WZ\FXT'YVP MJQ]3JMWDXIH*V_5%R-42V_W5P\4<($]O1[!+] MU'GXVA]-2G.>'EW7+;/2#"2*OK^OG]?T M5?V\58'RR"4CN&A;L2R-L[J^.E-`D1@E<7#WV$,6,CYB+[AD3R*X1%\ZP_X0 MW=V@F_Z@,^CV.[=H^-AY[/W4&SRB^X?>$/YV'OMW`V5>-5`H:#M+];W^X!H` M+@Q3&Y)E/EHDO>*%B_V!+.Q!O.H4,=J5&*RNX1+##5&V-DW04D`IX$R<.68E0=]CGR/2ID-+4)[DNV=2JJJXO:.0LZH MF$204B?"0$>]O(J;>V'A%Z`#SZN/>Q!V5+N*H@!0A,#_])YMY;98<0 M0A!U+L'JC2/8*1$5(',\AGD$@,@)EJJ0V-KI3Q#^@*8\!CG_")FMB73UQ]J, MMO=?5N/L$FR8M\-,/&6@"G1M.B=@2#RX*>2`^3Y1KU"A5SM%-9A.H`YC(:!$ MAQ@@8+\!@Y%E&M_B?EX^X0/!(G0!2=6(:\!!!FRE1@FA',%;Q2D+;!JJP&B-@^ MVS>>=^A)SWSN@:BSG'O`[0]71!_!H']_N((5.5R.*%B@#V@AB>-?%L?M=/O? MDD>#K(I%F-48Z%6@5W5S`H@(+O71'M&)*BU#O11>W8URD?GQ'_%35\CJ2!`@ M6(%>5>>6K5G9.YJ5T?$[,J%_<:^(?O/8ZLW%*2W%U4?[58X>8^86,6;N'F.I MA=;1S=6'.!VN2:76>4X^8"U.V3KZD`M&U%K;6J">,FGY\QU+47:/8#7' M^BSTS:OJXEH75T629=43JF3!^>EX%Y"27SJVD2Y"<:AZ.S*W3>4;A)Z:YOJ1 M([;@^3!G2A748->$P>J.9<%EV+M`2I>ZJJY4+JVZTD?]P8__`5!+`P04```` M"`"=6E\_+70B[`$%```"+P``%0`<`&-N8VPM,C`Q,3`Y,S!?8V%L+GAM;%54 M"0`#VKRN3MJ\KDYU>`L``00E#@``!#D!``#56FUOXC@0_MR5]C_DNA^XDQH" M12NU5;E52ML5$K=%[?7NOJV,,X"UCIVS'5[^_=J!T$!C`GW9A"]`XO%XYGG& M8WO,Y9=92)T)"$DX:]>:]4;-`89Y0-BH72.2NV=GG\_=9NW+GQ\_7/[FNDY? M\"#&$#B#N7-S_=6_ES%1X$@^5%,DX,3Q@PEB1J##PRA6()PN8WR"E!Y!GN@' M7#_1;=%5M;Q4\/CCAZ.C1/AB)LE:AVDK%6]Z M__W5>\!C")%+F%3&_$5'22YD\K['<>+`#D,Z5@GSY*9BKGGE-D_=5K,^DT'& MT"&AJV$ZWSH]SR#3.&\U,C)&RY[N/^NR!*!Y?G[N):U9::TN4"OQK/;/WJ)Q M0YIL,6<%JB;R:,&DX!3N8>B8[\?[;K[#GFGU2""^=TQWT4$148AVN(C\:Y@` MY5$(3#TH-`(3;8C-KQ`UH@]C`"4?&8H#'4;!L9,X>*'F$;2/)0DC"NF[L8!A M^Q@S3-UT7$/(I[<8UGMR&".*8YH$44\_KQD$,P4L>#+3N/W>B!C+EJ91CK/F MU*@)=BYJ68!JV4@8(CE(V(VE.T(H2LSS@"J9ODF@=!O-971_6K[^[DNIK4@U M4S0`VJYM-'IEFM:)A=``;K4PE@0-""6*@/19\*`X M_C'F5)LHC4]J;B&ML%OY[A1;7GIL[0I^-MS6/#R8V-J>C',$*T1-`0L'DIM] MC'FL\U,?S=&`VI+QIE2%:-B2@I_Y=E!4W(,&%8(^$L4S9:>N!TF:!85\)D\K MPN3.ZV7!"GDHBT^>5+49\@-]2$I,ZR,2=-GRF&6;7A;ILKG:C1VKK]5.A_IT M&W*6N+CUG+`I=ABD//>NVA-FL_9PPQ2(2!`)US`DF"B=M^,P3I+U=2ST.6>S MAX6_-U!\&(R_!8+Y,=+*QHB["I)++Z\N]785.DLY2O_62)DS[]WP+@*QJ`N_ M?:7NA]'S MWEL9V]5:=J4V!?U;RJ>_\-*Q8/@J7#X6F%C>A9-.#!M7,'T0A.OS+Q:`S*9[ M\;WE^FEG%26E$#WYC'U]P2=$\WLU?Y2@C5LE4!_KA+CMTF,/!64GFI=0FLU# M^V!5[56_*V5L9N?=,#EW:E#^14(@C<8M%P\@)@2#O!,=BDAH(WX_'65SOW^< MKZU`^^%5@RWN=]D$Y&NVW7D*RJ;ZG:9S+E;[)'%K06#98#[,_Z/U MFY]02P,$%`````@`G5I?/R,R/X?\!P``.&D``!4`'`!C;F-L+3(P,3$P.3,P M7V1E9BYX;6Q55`D``]J\KD[:O*Y.=7@+``$$)0X```0Y`0``[5W?<]HX$'YN M9_H_^-H'[F9J')++79)IKD-(TF$FES!)>KVWCK`$Z"HD3I))Z%]_DL%@C(5M M<(JS4'49Q#3_FD-"^8>'1T> MNXW:QS_>O/[PD^LZ'N/.V9O>.#O9B,UE+0_)4B,P(.2M$X(]D9,1.GTK\'!$4/1LP%'/B","KCU_J'W^3FOSML8T M4$"X'W21JYXBJGM2B1C3M&^/>:[+A:@'`B)+1+RJNU2\;`APF0Y>45T"VE"1 M.T3#+N)E0EW2&\,9@4PB7`H?7H@-0_[UG/F!,EI&KTT*+ZC$VP.B&_:U0+A] M`$8A5@\1*:(GH8_=O<9LC'XW>_Q5H91(P[T'78*B&@CH(G):,PAY.X:JN$-M M]59DP5T([@BRHG_(Z)UD_C=%]@T/D<&_``E0!_&[@6H`!AORE(P;M6C93;YL MGHKD41VSH+YL76;4CTKW.!NN=7)4+2MFAA,(!8F--'A`:@[C$/%I`K][VD*( MHAG(`>/X.X+9=*V4J!9-JP:GT[-O$3UM(8+\U,RDJTA+9&@Z)0<)2LJU2LTP MMK$E.=#,,._5#Y5TF!R>^(Q*-0Q?D%#NM"907[])FNM9E_/L*,VQ-[-Y26:> M83+3%$)QW.P*R8$O#7`30A4(LDFSK,M&I@!;`=>SA5SN3\KNE(7T9K/*P(J! MUA'1`F*@)N'ZY>+?`(\!47A%4[8`YQ-,^V%::\I"X!;=?<;3:0F3CXS8I<+C59W7!IJ`K\9)N>SM;O+]OH M96VC&S:-YT:(F][-"/'I@?KRM],WK/X';JMOB/!E>_WY;:_?JJ9``^.4>_YU M!2+OPA3KIA*SWD3[%X\C1`7*.L]@EJ\`#VN,M6XB\0E1!9:HD;H)A\J9&JC$ M8S2#;J`GJ]1.2JS M(;IBPL1#FF258EC<0.NFN@MPE\K&ELK`,0T4Z$7R=H9ZC*.IW#UX1.)0^;<@J3=&5H2S'4NI7[:R0S0^*R3`7< MGS#*NM6F"\"IZL0BNMMS!H0QP*7+5H`$@Y'Y%I-^(!E?D/Y5`@2;8Q52^^@Z MT(;?]*8W26X"J2^RZQ]'6$=2,1T5(*^@4]))/7I9(7SJBS;Q%3!]T/B2L(.$FHWH++MYD('Q9(7Q^*X1J]-=,=S@;8]6LSB:?!8)M.I\A-7V)Q]/]CO6+ M6ALHJD!HW\0]UBVJ5"QMW;Q)%DYK=WK^Y)]`R##8WK-;I(9/'Q.TA/J>E=,U MGZ2J9]!$GH8"ZY;S]`5OG0&HC%3O5S+]]^7K!.477G!6O=4Y7^G&+$ MUMQ:V9]S-.;-.+=PM#>`O\14Y3`E].=UBJK;G]>ZQ[J8K=#[",%P]W.1G<;N M8A@HS2YG8^_-T73C#.=P3H4[[=:=]3E07,1=U@W&Z3^`TD$<,YB<09A.1151 M48&@7,PEUAW@>.8_[;,-ASE_UV>'1SWN@M%HNI4)2+05%ON-Y*S;M#E+5X#` MW(ZP[N!(6]]W4ZFYONYH7+:*B>R6C&+M;7E]*6ZG=4E,[+3=6B:6I:I+1L): M*Q,-;=`UH[YZNYB^4IB2*9UCX1,F`HXR0M[6:BL0"[=WW-.;407(XKC+QO_-H:3JG_`?/I2$`L``00E#@``!#D!``#= M7>UOVS8:_[P!^Q]XW>&R`76'1`4`X M(&&$9^\.(D8&WWWWS\F_!(G7 MX-71T7>#5T?'QX?@\?'Q$(4S2"79PX#,P6`@>,<1_OA&_'O7A( MDL6;X5!4>KJG\2&ALR$G]GJ8%7SQQ>>??28+OWEBT4Z%Q]=9\>/AO_]U.0D> MT!P.(LP2(7Y:D45OF'Q^20*I@`%+H"PAO@VR8@/Q:'#\:O#Z^/")A3E!IU&\ M87-Z=7HY%)8Y.GE]E"LCJ-14?Z_*V@#')RS02BL-NY+Q!M&(A.>XF;"% MVAU+/4D@32SDSM7O3/([/LBA1C+G:G8G+4E@W$S:;/!A7T@#;('_&.%=.L2PX#PL7F1##)!9?4I)?,JVV:LB8G% MAC:8F4)V+P5?LL$,PD4*'!0G+'M21-#Z\1\_(8PHC$R!NVJKB,_N[Y\_,!2.\46$^2J<>W:C@'>3*(E0<2IM M0,`:C_6%M8$EYP8"S@XLUOR$'SO->`&X8:9#JA\J)IN%7EMZ]M$CZ]NJV#&; M@K>[_GD9P?LHEB+PR4L.(0\DYG9FY_]=1LGSZ%Y,94&BZ)W&U:W[9EU!;7KF MY7CT?GPYOAN?3\#HZ@Q,[JY/?_[G]>79^>WD'W!!V/?@[/QB?#J^\PVR=:U4 M!&RS]NQP0<-[$Q=,_!$"\8F<+_#9B/I21S$`$W"/9A'&8N(@4Y`2^P3TS:)C=;5%_+F1 MGKVL6.O8:F_-6K\W=C?,7-,9Q-%?,LY^2C`C<13*+USB&XXB+JK\>CU=3^4P MEFONN=1!/V6ZH6T]3#E5T688RPLB=F-RHLAND1=&](6-.&`KCV\]PZEQBSVG M!0#U[@^.\0JQQ,(?+"/0EC^H$=:Y/QAEO+KU!RU5K.\/UM73(W]08RM#?[`2 MO-WUS]H>8)L^7[M>WJ?CU=7WX_SSW$:,HEC*F5 MHY)1!+]+FO_Q#0/E*N_[)&I#=Y.X]QN"U"QM;UO28=+>'GN7*7N"N.\)>WL& M4*?K*1J@+9R<\S5D\OPKBN.?,7G$$P09P2@<,[9$M`0M^O)6F#$2Q08Y*0,@ M.`P^"A8@XP%2)CX!R,@:>1C5:)FN?5[NB:SS`=\CC*:1*@JB*NW(5U6*8;62 M\M?W5.I;[E=6V+WMF>J.D]5,3_)G)W-2GI&3B4@0]`4!*D7+)IQ]DW8W,-Q0 M$B`4RD"&&*+$T:3K:2Z?4S%$5->S'BR,1;,!3\8$B&8#03Y1-Q(C=@BFA,K= M(E^05=L\Q5&F9M/UX"UQ:;C!+V+R6!6OUU9QYTEI!'+C5Y$ID&DXDH5O2#,Q M@]+7JFR87@XC:-/TBL5<'C-PEWR7&ZI>@K\?'AT=;X\6?`]>';T\.I+_`!/I M]PS`9?)`:/07"K\'W[X\_F;GQ_58)])=R#(1)U3%J6??@*BRH^8X0J]97+ED MUM,EI;PWF&P;>JH-H$E&UC9'U^%M,S"5 MEW44_&X10C[O,TAN\P%K)<+&+I0,,X9II7Q$6,:QM'R&I)Z95L"3' M:ALL`3EN;WR!74/K[,50FK1BG]ZML5?;AC?K9!-)YKD$*4$0;WFXS,VQ$]T@ M3Z>F_'[XXN8^N!>^MXG/[=C7=@_PMO+.VH6USVEH%6#6P*.7,+B\F87)U(2P M.AJ^4]IE4+Q,#,$]%6MT(O.W6;(YXWA$4F2U.3JBYW[BH%=+:# MMST8G+'R#75US*+9T3-LN![2FQ"[@9%J*"N652QE'Y0I9VMUJ']-DJ_\)$W?,*)0>2^\ MH3.UCVL]ZS5>EVL[5\/1[M4W7RTYOZ_%#3C;X\B=WO1CJ6G-FWZ:J^OW?8->';M4K#4,6J[=H[MKEK=H0:CH'")< M6GK.6UO@&?K._04_(^5A\U[ER,?J^VMC"<31=R<0LVV,HNZ^2D!UOQ028_^%UH M`*0*WETIU%<;.KULVQK]G6[A4P09.D/IWS$NK/#%J\V"@"Y1F$L)5._T-R'F M(B'`0@F;[IMQ!A'OKD4W4+[U+F4+D*=A"#O3E60=6`.@TX!UY;6=?]P> ML\9AR7L:?.8. M&%TG>6^E..:N51,I+!!LR M9B"4W$#R@/@B=,.2KU$Y3Y>KZHXL<)):`*.9(*1:A[LT1!\]W9TQBX."Z\[2 M89I)&,K#3C`6!UG&^!0N(NYMJ3)+%*7MDTGT8ECECVQ(RR-(@PB#(*7N&SXK MC+"7+&+2&#T+*$94G454+.=@KE"2R1HF&ZK559S>;V65C#[+;?<)54R,MO-%IQ+_0PVY-PHV?-%75I# M::[M,H!HRTG5?*R@,![C$#W]C(J=2EW.1>IT.6L7V=(I92!)`T[;%^14*E^2 M$:TS?+<;<1RLXH\`Z0K&8I))KP,M)A1I-MV,23C98*LKL),DLZ\RJE\#&2/R M[^TX34Q3ME'6K#&[O,R-)6*$S<[BJ7!9+.;@^K9RQO8K`I,,Q2ZE-9C??4VJ M5*F]?[V<#A[=H?D6K1!>*E&\^=D:O45&-JC-:/G6^$4=BXU>;LU>G)]J/\>I M2].*]]*2>]*>)^(;7@W2NIWE:ILZ$*,YPJ%\*7`,RPY@[OYNY3"4LK**.F4$ M@:#H2VLK5#JAT(-0UW%\%O2^.%2KSUT%O7X/H&Q`-K%!Y+;2J5=H-L,E= MT%.8H!FAZO#:;BD'P;52M@Y":Y(NR`C[`I,*O?>C:AI[MP6']04:%Q$+8/P; M@E3]FB-E42M@5`E@-8RL[SU)B0-!W`L``00E#@``!#D!``#M7=USXC@2 M?YZMVO_!EWW@KFH(87)S-TE-;HN09(O:7))*,CMW3REA"]"MD'R23,+^]2?9 M?!AC^0,,EKB\!&*WI.[^M5K=^N+KSV]C[$P@XXB2BT;[^*3A0.)2#Y'A10-Q MVOSRY?-9L]WX^1\__O#U3\VF\\"H%[C0<_I3Y_KJE\XC#Y"`#J<#\0H8_.AT MO`D@BJ!+QWX@('-ZA-`)$+(%_E'^XQY_E._\*4/#D7#^W/V+\^GDY$OSTTF[ M?>R\OKX>0V\(6%CML4O'3K.IVL:(_'ZN_O0!AX[DFO"+HY$0_GFKI0J]]1D^ MIFS8DI6=MN:$1S_^\.%#2'S^QM%*@=?3.7F[]:]_WCZY(S@&342X4.Q'!3DZ MY^'S6^J&`A1HTM%2J/^:<[*F>M1L?VJ>MH_?N!=C=(#PHIGN7?>VI31S-1%(3'MD0-DXQ.;(":4X%U,? M7AQQ-/8QG#\;,3BX.'*)BYOSRI76?RI<=VO)NL\@EV3A\UOY8*59^"8@\:`W M;UA)4(EPJOT9`YBZ\38;6!DG98VXK(UU6:5=O60UT>ESP8`KYO5@T(?XHE&X M6*LLBW'CXM`]'M))RX,HU)#Z$K+?/&G/NLA/\M%+U/PC'"+5*A%W8`P3#&O) MX@S&0>RP568!<^=5RJ\A@@VM;<\H6KYT?D0TW1'"WKST@-%Q"07.F:`9,C@! ME]Q07Q4$N.%0YD$6.>Z]Z'\NR+.L-D7O*Z\MT_>J:.EZ_K1O/3]`AJB4P;L" M(DOAJW26:CXA;#H$I_N"H"-9\A1;-Q@,4U2_^MXRE2>$2U?U7_>EZHCMKF2' M`=R3X^?;KW"J=>M).LM4KQ$V'8+/^X*@&S`EZ`WB+L#_AH#I?8Z6U#(@]"*G M8_&W/7<'.AY3\B2H^_O32`K/[P.AXFB5F^G[1E8AR_`IHH9TI/Z^7Z1N$(:L M*RUG2)G>;:U268E%0M!TY7_9)>O$C]"D3TB:>I!X#KN\@Z>16PJ$3/1V7 ML_WB\AO%@50BBXQ&#TB2SDHDUH35I&DG^\7@.\3X5T)?R1,$G!+H]3@/(--B MH:.W$A.M\!IL]IY#+P./&_DDK8?H*"W#0RNP!HF]9]D18U'Z60R+.*W5:*P( MK<%CD7)_;:7.@&X\K=M5L\(RH/"1`+A+F=^Y@A.(J:_XDZ/9$*I%!$"FEP`K MTJ<1A()_(R#PD(#>0ZB;$11("K+I]&^E/.QRFKA21K?I70/`^Z&A!KPY!,"/ MNAC$@L^?)/O:[/&+"E"@8O=^<(.(9!))`Z0<94P_ERJZE=.H0*QGT,?)C%E# M5)/3V`0)Y3ATHNYH.KH"+&2?@SWY->G+,PA-P63%C%*U'Q/..`1B";OT.?``RL$FS.$UD!0I:0I&:^85QZF0"DP&+IIIZ01B1!GZ`WKY@*V5L`VH M=9%WM`14(4!A1E,8G!FUG<#,1L#)1JAN>,F/,06%SBT`?81E9RL2> M>&$V.:)8RL.5/Q#3G(&J<'$K\"VNC!UMO*P$QV(A1D:!FK$J:Y(:!,T/0SJN M2P,YW#Z`JST M#(*B`F=WJ*%)/IQUXU@ZP,@Z46`=5*7C1MLCQ?*QX=;'%"I9%,NX+J1YL8+GH8B;!X"\'IDM$.EB!@VU5:AH138NADBNT%T3`9G/$(=7<(!< M)&08%(R#,"J]"A@BPV0)#8X55&P5Y%4H4I]>%QT:SZ*AD<"A:L>PP;'PH%@_ M\IL-AEGGPZP+;O)"]`VGQNS`-E]X_?FR+9'>^485S::,A6+X_>#>ARRZEZ7Z M#2L;-K_7C2L;\EA/1^T1EX[A@K><%$1'7??6"'NVJ>3H^WUGROO.E!((/$I7 M0P+M7,_BM2G:SAPVE\(8I^>9OR;#ZS",=0U`>:5JABG7WN)HY6K`N.[4I5RHT'@NG79R+4%F$RKK M,A[0,L-"$U$X=8C(%P*=:-U$Z7$BEK(,5=IB:7<$`9 MC.B>P1OD5_(+%\C50+U-C5:8Q%8JV]%=6-L:@.1RYJ$NY3`R0-F9WSJU1<"E MB&KIV)=,E#>!>,^Y#=#]:N^,J"J5P=5L!74BTY-W#5=AHR/H6JMM_? M8/JZQU.1."I^.G*]2-WSG?9,-Q?1_/N<\_N<<[D059G2 M`Z,3)+W8Y?0;AUZ/+/+ECBO0)%K\S.[B&U1D"H)YP6YI!9F(LEV)R.9F63I1 MJ74[W'\"+L+Q_9D^0I<2%V&XPO4SK:9[[J2I@S"2W8!@W,J*NAM%A9TR3U!; M6#K$^PZ8^LD(?D/9$V03Y,KD@74Q0-I1N%P==9\WW6'G6IF.*J=8XYR05`># M0.U-C#Y[)''<12U%N2X+H)=_'F'#ROY?3&5#51OG3(I[WJVCQ;IMH[)(I+#" M#FA92B-VCTS4.LKVV456139G%YD*LL4;I`BQ-;IUH[JY06^&>E:\<"C>8';! MU_;>(*LBF[U!IH*,NX=!!LAE%'9`&\G2[]**?CT@F?OH=@F6J<(*IUY.*<9M+#KXF^*V0;'@ M-7&?RW=F/[0/R1L3!G;I"N%_:1^0`4AAJML.Y<]_Z;3>L[N![^-0/0#/%YWS M?Q"Z;&DK3*"P*HS;2-53)]!E;JFN(-#.W,9(ZH:CG,VM3K'&)34NDHYM)L[$ M8I7*9C@2\AHW>347Z(X25WY=SL$0+R56W#<]X9V4KJKNL`W#;,Q[H^\9[0D*`!'-D550) M``/:O*Y.VKRN3G5X"P`!!"4.```$.0$``.U86V\B-Q1^WDK]#RXODTB9&VFJ M$$%6E&Q6D=(0)5VI;Y$9>\"JL:>V!\+^^AY[9F"`0&%AI55WG[!]+M]W[.,S M^+3?OXXYFE"EF10=+PXB#U&12,+$L.,Q+?W+RXN6'WOOKW_^J?V+[Z-')4F> M4((&,_3AYF/W2>?,4*1E:J98T3/4)1,LK$)/CK/<4(7NA)`3;`!!G\$D">O=.)6J=0[#8&,4& M0/-6JO$-37'.3[E+Y(BR$E6JN_2'&V5PWQ7K@=$M!_6C@3-^U,62& M<9EAIS#/,B92Z2;OVI;Y547_B:;(A7UE9AGM-#0;9YPVRK61HFFGD8B$^]66 MOV2*!L"K4E&2@]G&L*TX!!,-1^T8W2^`*Q=8)6M>UHX%G,B,*L.HGN]](SQ. M2(2F^X8$)DRP;S4@C@?[!@0FE'^+L228[QL+F"0Y_\KI9GW\"3$@._CT=#?W MMU2A"D*,J)>>O?VJAS-F,.])E=W0">4RLT7PV>`AM84=BQF,C:N,NI_V@4)1 MX3\)G!,HW:2!&.DTCNFP"*J,:I'7UW'SURB*D(_F#F!<@*(2%5G8`)W4D)&# M1B7VZ<)8(YFB!3XZF3,X;8>KV'5*N::D+Z[=>+62E):ERB:KY7!(;MPPG7"I[!-DC/B)EU!'FO!]]-;)N`L&.:+'5[D MQK$<;LH-N&M%;BR`8%+'LG]&:F@("X+J>#8;YHBU+/GNJ MSR-*S4[U84]'&^M"M'-=Z*(ME:&$107NCWKP)3E0K^T]K$>W7$X/RH7_<+@Q M)RZ:S6/DQ/+7PA)`CL&/[*A_+622VSVJ?J&2?Q"&F=D=_,E78\>B]BG817O3 MN=HJ'[LZ7UK7A[:D%ZY0S==W?SP'UMU'>.X+,Z*&`>NC5?-EK]N.N_E52SLZ M66+R/[K,[;#VS(;)TAN\#<\T"._.KGH%OE_RX"0_\X%43 M#XFUMLB6AD.X+P%B5&A?9Z&`>ZY88N%;%C[^;2?X5?M#&$CQ<"@)*?PO)E+K MQE@"%YN@WVS?[(+F#-]LZ(24&UVM^(L6SR8*V[I":&@5=H:*.8&-Y!6;): M'L(#6,&)J?Q`H?12QE^V?>>ZI8V'=`Y#9G*[^E')/*M@H$J-BP@[WFZN;'CM ML-A4&/X+4$L!`AX#%`````@`G5I?/Z)1$:S["P``8E(``!$`&````````0`` M`*2!`````&-N8VPM,C`Q,3`Y,S`N>&UL550%``/:O*Y.=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`G5I?/RUT(NP!!0```B\``!4`&````````0```*2! M1@P``&-N8VPM,C`Q,3`Y,S!?8V%L+GAM;%54!0`#VKRN3G5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`)U:7S\C,C^'_`<``#AI```5`!@```````$```"D M@981``!C;F-L+3(P,3$P.3,P7V1E9BYX;6Q55`4``]J\KDYU>`L``00E#@`` M!#D!``!02P$"'@,4````"`"=6E\_7"6W(LD.```WLP``%0`8```````!```` MI('A&0``8VYC;"TR,#$Q,#DS,%]L86(N>&UL550%``/:O*Y.=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`G5I?/QEKY!+:"0``;XL``!4`&````````0`` M`*2!^2@``&-N8VPM,C`Q,3`Y,S!?<')E+GAM;%54!0`#VKRN3G5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`)U:7S^>$FQ#4@0``/P5```1`!@```````$` M``"D@2(S``!C;F-L+3(P,3$P.3,P+GAS9%54!0`#VKRN3G5X"P`!!"4.```$ :.0$``%!+!08`````!@`&`!H"``"_-P`````` ` end XML 18 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended 176 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Cash Flows from Operating Activities
Net Loss $ (5,935) $ (4,740) $ (105,478)
Adjustment to reconcile net loss to cash provided (used) by operating activities:
Common stock issued for services 0 0 17,200
Increase in accounts payable and accrued expenses 4,825 7,900 53,175
Net cash provided (used) by operating activities (1,110) 3,160 (35,103)
Cash Flows from Investing Activities
Net cash provided by investing activities 0 0 0
Cash Flows from Financing Activities
Proceeds from common stock issued for cash 0 0 36,000
Net cash provided by financing activities 0 0 36,000
Increase (Decrease) in cash (1,110) 3,160 897
Cash and cash equivalents at beginning of period 2,007 1,230 0
Cash and cash equivalents at end of period 897 4,390 897
Supplemental Cash Flow Information:
Cash paid for interest 0 0 0
Cash paid for income taxes 0 0 0
Non-Cash Investing and Financing Activities
Common stock issued for services $ 0 $ 0 $ 17,200
X
- Details
Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details
Name: us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details
Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: na
Period Type: duration
X
- Details
Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details
Name: us-gaap_IncomeTaxesPaid
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details
Name: us-gaap_InterestPaid
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The net cash inflow or outflow from financing activity for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInFinancingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The net cash inflow or outflow from investing activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInInvestingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: na
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details
Name: us-gaap_NetIncomeLoss
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details
Name: us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_SupplementalCashFlowInformationAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
XML 19 R2.htm IDEA: XBRL DOCUMENT v2.3.0.15
Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) (USD $)
Sep. 30, 2011
Dec. 31, 2010
Common stock par value $ 0.001 $ 0.001
Common stock authorized 20,000,000 20,000,000
Common stock issued 6,150,000 6,150,000
X
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: us-gaap
Data Type: num:perShareItemType
Balance Type: na
Period Type: instant
X
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_CommonStockSharesAuthorized
Namespace Prefix: us-gaap
Data Type: xbrli:sharesItemType
Balance Type: na
Period Type: instant
X
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_CommonStockSharesIssued
Namespace Prefix: us-gaap
Data Type: xbrli:sharesItemType
Balance Type: na
Period Type: instant
XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.15 Html 11 47 1 false 0 0 false 3 true false R1.htm 000010 - Document - Document and Entity Information Sheet http://CNCL/20110930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information false false R2.htm 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) Sheet http://CNCL/20110930/role/idr_CancerCapitalCorpADevelopmentStageCompanyBalanceSheetsUnauditedParenthetical Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) false false R3.htm 104000 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) Sheet http://CNCL/20110930/role/idr_CancerCapitalCorpADevelopmentStageCompanyBalanceSheetsUnaudited Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) false false R4.htm 124000 - Statement - Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) Sheet http://CNCL/20110930/role/idr_CancerCapitalCorpDevelopmentStageCompanyStatementsOfOperationsUnaudited Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) false false R5.htm 152200 - Statement - Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) Sheet http://CNCL/20110930/role/idr_CancerCapitalCorpADevelopmentStageCompanyStatementsOfCashFlowsUnaudited Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) false false R6.htm 200000 - Disclosure - Organization, Consolidation and Presentation of Financial Statements Sheet http://CNCL/20110930/role/idr_DisclosureOrganizationConsolidationAndPresentationOfFinancialStatements Organization, Consolidation and Presentation of Financial Statements false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 104000 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Apr. 10, 1997' Process Flow-Through: 124000 - Statement - Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) Process Flow-Through: 152200 - Statement - Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) cncl-20110930.xml cncl-20110930.xsd cncl-20110930_cal.xml cncl-20110930_def.xml cncl-20110930_lab.xml cncl-20110930_pre.xml true true EXCEL 21 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P93EB.&1E,%\P9#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A;F-E#I7;W)K#I7 M;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P93EB.&1E,%\P9#'0O:'1M;#L@8VAA2!);F9O2!);F9O M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M,C`Q,3QS<&%N/CPO'0^43,\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P93EB.&1E,%\P9#'0O:'1M;#L@8VAA M'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0U,2D\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!F:6YA;F-I;F<@86-T:79I=&EE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P93EB M.&1E,%\P9#'0O:'1M;#L@8VAAF%T:6]N+"!#;VYS M;VQI9&%T:6]N(&%N9"!06EN9R!U;F%U9&ET960@8V]N9&5N M2!T:&4@0V]M<&%N>2!P=7)S=6%N="!T;R!T:&4@&-H86YG92!#;VUM:7-S M:6]N+B9N8G-P.R!#97)T86EN(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T92!D M:7-C;&]S=7)E2!I;F-L=61E9"!I;B!F:6YA;F-I86P@

Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2011	Dec. 31, 2010
Common stock par value	$ 0.001	$ 0.001
Common stock authorized	20,000,000	20,000,000
Common stock issued	6,150,000	6,150,000